Squarepoint Ops LLC Has $688,000 Holdings in Haemonetics Co. (NYSE:HAE)

Squarepoint Ops LLC reduced its stake in shares of Haemonetics Co. (NYSE:HAE - Free Report) by 80.6% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 8,318 shares of the medical instruments supplier's stock after selling 34,579 shares during the period. Squarepoint Ops LLC's holdings in Haemonetics were worth $688,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of HAE. Commonwealth Equity Services LLC grew its stake in Haemonetics by 3.3% in the second quarter. Commonwealth Equity Services LLC now owns 3,673 shares of the medical instruments supplier's stock valued at $304,000 after purchasing an additional 117 shares in the last quarter. QRG Capital Management Inc. grew its stake in shares of Haemonetics by 6.9% in the 2nd quarter. QRG Capital Management Inc. now owns 4,031 shares of the medical instruments supplier's stock valued at $333,000 after buying an additional 260 shares in the last quarter. Arizona State Retirement System increased its holdings in Haemonetics by 2.0% in the second quarter. Arizona State Retirement System now owns 14,217 shares of the medical instruments supplier's stock worth $1,176,000 after buying an additional 272 shares during the last quarter. State of Michigan Retirement System raised its position in Haemonetics by 2.5% during the first quarter. State of Michigan Retirement System now owns 12,474 shares of the medical instruments supplier's stock valued at $1,065,000 after acquiring an additional 300 shares in the last quarter. Finally, Dynamic Advisor Solutions LLC lifted its stake in Haemonetics by 2.1% in the first quarter. Dynamic Advisor Solutions LLC now owns 18,300 shares of the medical instruments supplier's stock valued at $1,562,000 after acquiring an additional 374 shares during the last quarter. 99.67% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research analysts have recently commented on HAE shares. CL King assumed coverage on shares of Haemonetics in a research note on Friday, September 13th. They set a "buy" rating and a $116.00 price target on the stock. Citigroup lowered their target price on shares of Haemonetics from $94.00 to $85.00 and set a "neutral" rating on the stock in a research report on Thursday, August 22nd. JMP Securities reaffirmed a "market outperform" rating and issued a $125.00 price target on shares of Haemonetics in a research report on Tuesday, August 13th. Bank of America began coverage on Haemonetics in a report on Wednesday, September 11th. They set a "neutral" rating and a $85.00 price objective on the stock. Finally, Needham & Company LLC upgraded Haemonetics from a "hold" rating to a "buy" rating and set a $112.00 target price for the company in a report on Wednesday, June 12th. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $106.14.

Insiders Place Their Bets

In other news, insider Stewart W. Strong sold 4,312 shares of the company's stock in a transaction dated Friday, July 26th. The shares were sold at an average price of $91.15, for a total transaction of $393,038.80. Following the completion of the transaction, the insider now owns 18,196 shares of the company's stock, valued at approximately $1,658,565.40. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Haemonetics news, EVP Anila Lingamneni sold 2,136 shares of Haemonetics stock in a transaction on Thursday, July 11th. The shares were sold at an average price of $90.00, for a total transaction of $192,240.00. Following the sale, the executive vice president now owns 21,410 shares in the company, valued at $1,926,900. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Stewart W. Strong sold 4,312 shares of the stock in a transaction on Friday, July 26th. The shares were sold at an average price of $91.15, for a total transaction of $393,038.80. Following the completion of the transaction, the insider now owns 18,196 shares of the company's stock, valued at approximately $1,658,565.40. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 1.80% of the company's stock.

Haemonetics Stock Performance

Shares of NYSE HAE traded down $0.51 during trading hours on Tuesday, hitting $76.68. 495,711 shares of the company's stock were exchanged, compared to its average volume of 541,747. The company's 50-day moving average price is $77.47 and its 200-day moving average price is $84.06. Haemonetics Co. has a 1-year low of $70.74 and a 1-year high of $97.97. The stock has a market capitalization of $3.91 billion, a price-to-earnings ratio of 33.48, a PEG ratio of 1.19 and a beta of 0.30. The company has a debt-to-equity ratio of 1.35, a current ratio of 3.76 and a quick ratio of 2.33.

Haemonetics (NYSE:HAE - Get Free Report) last issued its quarterly earnings results on Thursday, August 8th. The medical instruments supplier reported $1.02 EPS for the quarter, missing analysts' consensus estimates of $1.03 by ($0.01). The business had revenue of $336.17 million for the quarter, compared to analyst estimates of $335.08 million. Haemonetics had a return on equity of 21.86% and a net margin of 8.61%. The firm's quarterly revenue was up 8.0% compared to the same quarter last year. During the same quarter last year, the firm earned $1.05 earnings per share. On average, sell-side analysts expect that Haemonetics Co. will post 4.57 earnings per share for the current fiscal year.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.